Back to Search
Start Over
The relationship between allergen immunotherapy and omalizumab for treating asthma.
- Source :
-
Expert review of respiratory medicine [Expert Rev Respir Med] 2015 Apr; Vol. 9 (2), pp. 129-34. Date of Electronic Publication: 2015 Jan 12. - Publication Year :
- 2015
-
Abstract
- Allergen-specific immunotherapy (AIT) is considered the only treatment capable of modifying the natural history of allergic respiratory disorders. The possible adverse events related to AIT have, until now, limited its use to mild and controlled asthma. The pre-administration or concomitant treatment of AIT and omalizumab (an anti-IgE humanized antibody), recommended for the treatment of severe allergic asthma, could be useful in reducing the adverse events due to AIT and to allow its use in patients with more severe or uncontrolled asthma. AIT/omalizumab combination has been explored in a few trials on asthma patients and also in other allergic disorders, such as rhinitis, hymenoptera systemic reaction and food allergy with significant results. We are at the beginning a new era where phenotype/endotype-based treatment will be associated with drug mass therapy and/or nonpharmacological phenotype/endotype-driven treatment to optimize disease control and/or to make the use of other treatments safer.
- Subjects :
- Animals
Anti-Asthmatic Agents adverse effects
Asthma diagnosis
Asthma immunology
Desensitization, Immunologic adverse effects
Humans
Omalizumab adverse effects
Severity of Illness Index
Treatment Outcome
Allergens immunology
Anti-Asthmatic Agents therapeutic use
Asthma therapy
Desensitization, Immunologic methods
Immunoglobulin E immunology
Omalizumab therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1747-6356
- Volume :
- 9
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- Expert review of respiratory medicine
- Publication Type :
- Academic Journal
- Accession number :
- 25578528
- Full Text :
- https://doi.org/10.1586/17476348.2015.1000866